B7-H3 CAR-T for Recurrent or Refractory Glioblastoma

Inclusion Criteria: * Documented informed consent of the participant and/or legally authorized representative. * Histologically confirmed diagnosis of World Health Organization (WHO) classification grade IV glioblastoma (GBM). * Clinical Pathology confirms B7-H3 positive tumor expression by immunohistochemistry (IHC) at the initial tumor presentation or recurrent disease (H-score \>= 50). * Relapsed/refractory disease confirmed by radiographic evidence after standard therapy. * Suitable for the surgery of the placement of the Ommaya catheter. * Eastern Cooperative Oncology Group (ECOG) =0 or 1 (need to be confirmed before intratumoral or intracerebroventricular injection) * \>= 8 weeks after completion of front-line radiation therapy * \>= 6 weeks after completion of nitrourea chemotherapy * \>= 14 days after completion of Temozolomide or other chemotherapy * 2 weeks of wash-out time after completion of targeted therapy with related adverse events (AE) on baseline (4 weeks for Bevacizumab). Patients with other chronic AEs are in the investigator's judgement * Blood cell count： White blood count (WBC) \>= 2000/μL；Neutrophil count \>= 1500/μL；Platelets \>= 100 x 103/μL；Hemoglobin \>= 9.0 g/dL * Serum Creatinine \<= 1.5×ULN or Creatinine Clearance Rate (Cockcroft and Gault) \> 30 mL/min/1.73 m2 * Alanine Transaminase (ALT) \<= 5×ULN and total bilirubin \< 2.0mg/dL * Lung function: Oxygen (O2) saturation \>= 92% on room air and \< CTCAE grade 1 dyspnea * Heart function: Left ventricular ejection fraction (LVEF) \>= 40% by multigated acquisition (MUGA) scan or echocardiogram * Normal coagulation function: prothrombin time (PT)，activated partial thromboplastin time (APTT) and international normalized ratio (INR) * Good blood vessel condition for leukapheresis * Women of childbearing potential (WOCBP): negative urine or serum pregnancy test * Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity within one year after B7-H3 CAR-T infusion Exclusion Criteria: * Other active malignancy in the past 2 years except non-melanoma skin cancer, completely surgical removed low grade tumor, post-therapeutic limited-stage prostate cancer, biopsy confirmed in situ cervical carcinoma, PAP test confirmed squamous intraepithelial lesions * Participant is undergoing or planning to take other anti-tumor therapies * Participant is systematic steroid-dependent, or is expecting to be treated with systematic steroid * Active immunodeficiency virus (HIV) or hepatitis B or hepatitis C virus infection * Active infection from fungi, bacteria and/or viruses * Known history of the following cardiac diseases in the past 6 months: New York Heart Association (NYHA) defined grade III or IV heart failure, cardiac angioplasty, myocardial infarction, unstable angina and other clinically significant heart diseases * Known history and/or clinically evident central nerve system diseases: seizure, epileptic seizure, aphasia, paralysis, stroke, severe brain damage, dementia, Parkinson's Disease, cerebellar diseases, organic brain syndrome and psychiatric disorders * Autoimmune diseases * Pregnant or breastfeeding females * Therapeutic doses of corticosteroid within 7 days before leukapheresis or 72 hours before B7-H3 CAR-T infusion * Cytotoxic chemotherapy without lymphocytotoxicity within 1 week before leukapheresis except that the treatment has been stopped for more than 3 half-lives of the drug * Lymphocytotoxic chemotherapy (cyclophosphamide, Ifosfamide and bendamustine) within 2 weeks before leukapheresis * Other clinical trials drugs within 4 weeks before leukapheresis except that the drug has no effect or the disease has progressed, and the treatment has been stopped for more than 3 half-lives of the drug * Radiotherapy within 6 weeks before leukapheresis * Prior trials of CAR-T or other cell therapy * Any other condition that would, in the investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns with clinical study procedures * Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)